NextCure, Inc.
NextCure, Inc. (NXTC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nxtc · stock forecast · 13 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 13 Wall Street analysts in the past 3 months
Buy
13 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$15.00
Consensus
$15.00
+437.6% upside
Low
$15.00
Median: $15 · Last Close: $2.79
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.79 | ↑ 0.00% |
1-day model range: $2.72–$2.86. Peak: $2.86 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · NXTC · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-11-07 | Ladenburg Thalmann | Upgrade ↑ | Neutral→Buy |
| 2025-07-15 | Piper Sandler | Maintains | Overweight→Overweight |
| 2025-07-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-02 | Needham | Maintains | Buy→Buy |
| 2024-06-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on NextCure, Inc. (NXTC) stock. Of the recent 45 rating actions, 3 were upgrades and 4 were downgrades. 13 analysts currently cover NXTC.
Analyst Recommendation Trends
NXTC analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$3M
↓ 68.0% YoY
Revenue Next Year
$7M
↑ 112.1% YoY
EPS This Year
$-7.33
EPS Next Year
$-8.35
↑ 13.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast NXTC EPS of $-7.33 for the current fiscal year, based on estimates from 2 analysts. The NXTC revenue forecast is $3M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NXTC stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NXTC price target is $15.00 (+437.6% upside), with an analyst consensus of Buy.
The NXTC short-term stock prediction for tomorrow is $2.79 (+0.00%).
NextCure, Inc. trades on NASDAQ under the ticker NXTC. The NXTC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 85% of covering analysts.
Frequently asked questions
NXTC forecast · 8 questionsAccording to 13 Wall Street analysts, the average 12-month NXTC price target is $15.00, with a high forecast of $15.00 and a low of $15.00. The median price target is shown in the chart above when available. This implies +437.6% potential upside from the current price of $2.79.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.